Cargando…

The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients

RNA-binding protein pathology now represents one of the best characterized pathologic features of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration patients with TDP-43 or FUS pathology (FTLD-TDP and FTLD-FUS). Using liquid chromatography tandem mass spectrometry, we identifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Collins, Mahlon, Riascos, David, Kovalik, Tina, An, Jiyan, Krupa, Kelly, Krupa, Kristin, Hood, Brian L., Conrads, Thomas P., Renton, Alan E., Traynor, Bryan J., Bowser, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3472056/
https://www.ncbi.nlm.nih.gov/pubmed/22993125
http://dx.doi.org/10.1007/s00401-012-1045-x
_version_ 1782246523394850816
author Collins, Mahlon
Riascos, David
Kovalik, Tina
An, Jiyan
Krupa, Kelly
Krupa, Kristin
Hood, Brian L.
Conrads, Thomas P.
Renton, Alan E.
Traynor, Bryan J.
Bowser, Robert
author_facet Collins, Mahlon
Riascos, David
Kovalik, Tina
An, Jiyan
Krupa, Kelly
Krupa, Kristin
Hood, Brian L.
Conrads, Thomas P.
Renton, Alan E.
Traynor, Bryan J.
Bowser, Robert
author_sort Collins, Mahlon
collection PubMed
description RNA-binding protein pathology now represents one of the best characterized pathologic features of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration patients with TDP-43 or FUS pathology (FTLD-TDP and FTLD-FUS). Using liquid chromatography tandem mass spectrometry, we identified altered levels of the RNA-binding motif 45 (RBM45) protein in the cerebrospinal fluid (CSF) of ALS patients. This protein contains sequence similarities to TAR DNA-binding protein 43 (TDP-43) and fused-in-sarcoma (FUS) that are contained in cytoplasmic inclusions of ALS and FTLD-TDP or FTLD-FUS patients. To further characterize RBM45, we first verified the presence of RBM45 in CSF and spinal cord tissue extracts of ALS patients by immunoblot. We next used immunohistochemistry to examine the subcellular distribution of RBM45 and observed in a punctate staining pattern within nuclei of neurons and glia in the brain and spinal cord. We also detected RBM45 cytoplasmic inclusions in 91 % of ALS, 100 % of FTLD-TDP and 75 % of Alzheimer’s disease (AD) cases. The most extensive RBM45 pathology was observed in patients that harbor the C9ORF72 hexanucleotide repeat expansion. These RBM45 inclusions were observed in spinal cord motor neurons, glia and neurons of the dentate gyrus. By confocal microscopy, RBM45 co-localizes with ubiquitin and TDP-43 in inclusion bodies. In neurons containing RBM45 cytoplasmic inclusions we often detected the protein in a punctate pattern within the nucleus that lacked either TDP-43 or ubiquitin. We identified RBM45 using a proteomic screen of CSF from ALS and control subjects for candidate biomarkers, and link this RNA-binding protein to inclusion pathology in ALS, FTLD-TDP and AD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00401-012-1045-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-3472056
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-34720562012-10-18 The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients Collins, Mahlon Riascos, David Kovalik, Tina An, Jiyan Krupa, Kelly Krupa, Kristin Hood, Brian L. Conrads, Thomas P. Renton, Alan E. Traynor, Bryan J. Bowser, Robert Acta Neuropathol Original Paper RNA-binding protein pathology now represents one of the best characterized pathologic features of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration patients with TDP-43 or FUS pathology (FTLD-TDP and FTLD-FUS). Using liquid chromatography tandem mass spectrometry, we identified altered levels of the RNA-binding motif 45 (RBM45) protein in the cerebrospinal fluid (CSF) of ALS patients. This protein contains sequence similarities to TAR DNA-binding protein 43 (TDP-43) and fused-in-sarcoma (FUS) that are contained in cytoplasmic inclusions of ALS and FTLD-TDP or FTLD-FUS patients. To further characterize RBM45, we first verified the presence of RBM45 in CSF and spinal cord tissue extracts of ALS patients by immunoblot. We next used immunohistochemistry to examine the subcellular distribution of RBM45 and observed in a punctate staining pattern within nuclei of neurons and glia in the brain and spinal cord. We also detected RBM45 cytoplasmic inclusions in 91 % of ALS, 100 % of FTLD-TDP and 75 % of Alzheimer’s disease (AD) cases. The most extensive RBM45 pathology was observed in patients that harbor the C9ORF72 hexanucleotide repeat expansion. These RBM45 inclusions were observed in spinal cord motor neurons, glia and neurons of the dentate gyrus. By confocal microscopy, RBM45 co-localizes with ubiquitin and TDP-43 in inclusion bodies. In neurons containing RBM45 cytoplasmic inclusions we often detected the protein in a punctate pattern within the nucleus that lacked either TDP-43 or ubiquitin. We identified RBM45 using a proteomic screen of CSF from ALS and control subjects for candidate biomarkers, and link this RNA-binding protein to inclusion pathology in ALS, FTLD-TDP and AD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00401-012-1045-x) contains supplementary material, which is available to authorized users. Springer-Verlag 2012-09-21 2012 /pmc/articles/PMC3472056/ /pubmed/22993125 http://dx.doi.org/10.1007/s00401-012-1045-x Text en © The Author(s) 2012 https://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Paper
Collins, Mahlon
Riascos, David
Kovalik, Tina
An, Jiyan
Krupa, Kelly
Krupa, Kristin
Hood, Brian L.
Conrads, Thomas P.
Renton, Alan E.
Traynor, Bryan J.
Bowser, Robert
The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients
title The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients
title_full The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients
title_fullStr The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients
title_full_unstemmed The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients
title_short The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients
title_sort rna-binding motif 45 (rbm45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (als) and frontotemporal lobar degeneration with tdp-43 inclusions (ftld-tdp) patients
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3472056/
https://www.ncbi.nlm.nih.gov/pubmed/22993125
http://dx.doi.org/10.1007/s00401-012-1045-x
work_keys_str_mv AT collinsmahlon thernabindingmotif45rbm45proteinaccumulatesininclusionbodiesinamyotrophiclateralsclerosisalsandfrontotemporallobardegenerationwithtdp43inclusionsftldtdppatients
AT riascosdavid thernabindingmotif45rbm45proteinaccumulatesininclusionbodiesinamyotrophiclateralsclerosisalsandfrontotemporallobardegenerationwithtdp43inclusionsftldtdppatients
AT kovaliktina thernabindingmotif45rbm45proteinaccumulatesininclusionbodiesinamyotrophiclateralsclerosisalsandfrontotemporallobardegenerationwithtdp43inclusionsftldtdppatients
AT anjiyan thernabindingmotif45rbm45proteinaccumulatesininclusionbodiesinamyotrophiclateralsclerosisalsandfrontotemporallobardegenerationwithtdp43inclusionsftldtdppatients
AT krupakelly thernabindingmotif45rbm45proteinaccumulatesininclusionbodiesinamyotrophiclateralsclerosisalsandfrontotemporallobardegenerationwithtdp43inclusionsftldtdppatients
AT krupakristin thernabindingmotif45rbm45proteinaccumulatesininclusionbodiesinamyotrophiclateralsclerosisalsandfrontotemporallobardegenerationwithtdp43inclusionsftldtdppatients
AT hoodbrianl thernabindingmotif45rbm45proteinaccumulatesininclusionbodiesinamyotrophiclateralsclerosisalsandfrontotemporallobardegenerationwithtdp43inclusionsftldtdppatients
AT conradsthomasp thernabindingmotif45rbm45proteinaccumulatesininclusionbodiesinamyotrophiclateralsclerosisalsandfrontotemporallobardegenerationwithtdp43inclusionsftldtdppatients
AT rentonalane thernabindingmotif45rbm45proteinaccumulatesininclusionbodiesinamyotrophiclateralsclerosisalsandfrontotemporallobardegenerationwithtdp43inclusionsftldtdppatients
AT traynorbryanj thernabindingmotif45rbm45proteinaccumulatesininclusionbodiesinamyotrophiclateralsclerosisalsandfrontotemporallobardegenerationwithtdp43inclusionsftldtdppatients
AT bowserrobert thernabindingmotif45rbm45proteinaccumulatesininclusionbodiesinamyotrophiclateralsclerosisalsandfrontotemporallobardegenerationwithtdp43inclusionsftldtdppatients
AT collinsmahlon rnabindingmotif45rbm45proteinaccumulatesininclusionbodiesinamyotrophiclateralsclerosisalsandfrontotemporallobardegenerationwithtdp43inclusionsftldtdppatients
AT riascosdavid rnabindingmotif45rbm45proteinaccumulatesininclusionbodiesinamyotrophiclateralsclerosisalsandfrontotemporallobardegenerationwithtdp43inclusionsftldtdppatients
AT kovaliktina rnabindingmotif45rbm45proteinaccumulatesininclusionbodiesinamyotrophiclateralsclerosisalsandfrontotemporallobardegenerationwithtdp43inclusionsftldtdppatients
AT anjiyan rnabindingmotif45rbm45proteinaccumulatesininclusionbodiesinamyotrophiclateralsclerosisalsandfrontotemporallobardegenerationwithtdp43inclusionsftldtdppatients
AT krupakelly rnabindingmotif45rbm45proteinaccumulatesininclusionbodiesinamyotrophiclateralsclerosisalsandfrontotemporallobardegenerationwithtdp43inclusionsftldtdppatients
AT krupakristin rnabindingmotif45rbm45proteinaccumulatesininclusionbodiesinamyotrophiclateralsclerosisalsandfrontotemporallobardegenerationwithtdp43inclusionsftldtdppatients
AT hoodbrianl rnabindingmotif45rbm45proteinaccumulatesininclusionbodiesinamyotrophiclateralsclerosisalsandfrontotemporallobardegenerationwithtdp43inclusionsftldtdppatients
AT conradsthomasp rnabindingmotif45rbm45proteinaccumulatesininclusionbodiesinamyotrophiclateralsclerosisalsandfrontotemporallobardegenerationwithtdp43inclusionsftldtdppatients
AT rentonalane rnabindingmotif45rbm45proteinaccumulatesininclusionbodiesinamyotrophiclateralsclerosisalsandfrontotemporallobardegenerationwithtdp43inclusionsftldtdppatients
AT traynorbryanj rnabindingmotif45rbm45proteinaccumulatesininclusionbodiesinamyotrophiclateralsclerosisalsandfrontotemporallobardegenerationwithtdp43inclusionsftldtdppatients
AT bowserrobert rnabindingmotif45rbm45proteinaccumulatesininclusionbodiesinamyotrophiclateralsclerosisalsandfrontotemporallobardegenerationwithtdp43inclusionsftldtdppatients